Beacon Biosignals closes Series B round to advance its EEG based technology

The Boston startup Beacon Biosignals last week received Series B funding of 86 million dollars, with participation from Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, S32, Catalio Capital Management and Takeda.

Founded in 2019 by Jacob Donoghue, Jarrett Revels, Brandon Westover and Sydney Cash, Beacon Biosignals takes data from the brain’s electrical activity (EEG) and analyzes it with AI and machine learning algorithms to improve diagnoses, clinical trials and treatments for brain disorders.

Its main products are its headband called “Waveband”, which captures EEG during sleep and wakefulness, generating biosignal data that is then used in its foundation model “Beacon’s”, which seeks to analyze disease signatures and predict responses to clinical treatments for the brain.

With the funding received, they hope to increase their clinical validation, while also increasing or exploring the acquisition of new biomarkers; finally, they hope to expand their platform to be able to capture things like airflow, respiratory effort and oxygen saturation.

Founders: Jacob Donoghue, Jarrett Revels, Brandon Westover, Sydney Cash

Sources: Crunchbase | Beacon Biosignals